New drug shows promise against rare eye cancer before liver surgery

NCT ID NCT07057596

Recruiting now Disease control Sponsor: Grupo Español Multidisciplinar de Melanoma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that has spread to the liver. Participants receive weekly infusions for 6 months, then may have surgery to remove any remaining tumors. The goal is to see if the drug can completely eliminate cancer cells before surgery and help keep the cancer from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tebentafusp (a drug given intravenously)
What this could lead to: If successful, this could offer a new treatment option that shrinks liver tumors before surgery, potentially delaying or preventing the cancer from coming back.
What could go wrong: This is a small, early-phase trial with only 19 participants, so results may not apply to everyone. Tebentafusp can cause serious side effects, and it is not yet known if it will work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MESTASTATIC UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma Neoplasm Metastasis uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESTASTATIC UVEAL MELANOMA

Contacts and locations

Locations

Charité - Universitätsmedizin Berlin
RECRUITING

Berlin, State of Berlin, 10117, Germany
Consorcio Hospital General Universitario de Valencia
RECRUITING

Valencia, Valencia, 46014, Spain
Hospital La Paz
RECRUITING

Madrid, Madrid, 28046, Spain
Institut Catala d'Oncologia (ICO) Hospitalet
NOT_YET_RECRUITING

L'Hospitalet de Llobregat, Barcelona, 08908, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.